ARL3

ARL3 stands for "ARF like GTPase 3," and it makes a small protein that acts like a molecular switch inside cells. One of its main jobs is to help deliver fat-tagged (lipidated) proteins to the cilium, a tiny antenna-like structure that photoreceptors use to build and maintain their light-sensing outer segment. In photoreceptors, ARL3 helps position proteins that are essential for the visual response, such as transducin and phosphodiesterase (PDE6). ARL3 works closely with a partner protein called RP2, which helps switch ARL3 off at the right time so that cargo is released in the right place. Laboratory studies also show that ARL3 is needed for the connecting cilium to form properly, which is why problems with this gene can disrupt the whole light-sensing machinery.

ARL3-related disease has been reported as several different retinal conditions, including retinitis pigmentosa, cone-rod dystrophy, and rod-cone dystrophy. In retinitis pigmentosa, the rod cells that support night and side vision tend to be affected first, causing night blindness and gradual loss of peripheral vision. In cone-rod dystrophy, the cone cells responsible for central and color vision are affected earlier, and studies have described bull's-eye macular changes, central retinal thinning, and reduced visual acuity. Reports emphasize that the same variant can produce very different severity even within a single family, ranging from extensive retinal atrophy to no detectable disease. This means that a genetic result alone cannot predict how an individual person's vision will change over time.

ARL3 is an established cause of inherited retinal disease. A specific dominant missense change, p.(Tyr90Cys), was confirmed to cause non-syndromic retinitis pigmentosa in a family with early loss of central vision and central retinal thinning. Another dominant variant, p.(Asp67Val), was identified in a four-generation family with a widespread progressive retinal degeneration. Recessive disease has also been documented; a homozygous variant (R99I) caused autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) cone-rod dystrophy in two consanguineous families, and compound heterozygous variants were linked to early-onset rod-cone dystrophy. Across these reports, laboratory and cell studies consistently show that the disease-causing changes destabilize the ARL3 protein or disrupt its role in transporting proteins to the photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cilium.

It is not fully understood why variants in the same gene can lead to such different diagnoses and inheritance patterns, ranging from dominant retinitis pigmentosa to recessive cone-rod dystrophy or syndromic Joubert syndrome. Some ARL3 variants show incomplete penetrance, meaning a person can carry the change yet have little or no visible retinal disease, which complicates predictions and family counseling. A possible role for mitochondrial (cellular energy) dysfunction in ARL3-related degeneration has been raised, but this evidence comes only from patient-derived cells and cultured cells in the laboratory, not from patients directly. The Joubert syndrome connection appears rare, and much of the detailed mechanism has been worked out in mice, cultured cells, and the related RP2 protein rather than in large groups of people with ARL3 variants.

The supplied records do not identify an approved treatment that targets ARL3 specifically. Research is active but early, and much of it aims to understand how different variants damage the protein and the photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cilium. Human stem-cell models made from a patient's own cells have been used to show that a dominant ARL3 variant reduces the delivery of key proteins into the cilium, offering a tool for future therapy testing. In mice, delivering a working copy of ARL3 with a gene-therapy vector restored cilium formation and slowed degeneration, but this is animal research and not an available treatment for people.

• A dominant ARL3 variant with striking family variability

  Human family study with laboratory functional testing.

  What was found:

  Affected relatives had non-syndromic retinitis pigmentosa, but severity ranged from extensive retinal atrophy to no visible disease, independent of age, and the variant disrupted normal protein levels and ciliogenesis.

  Why it matters:

  It shows that an ARL3 result cannot by itself predict how badly someone will be affected, which is important for counseling.

  Limitation: Findings come from a single family, so they may not represent everyone with ARL3 variants.

• Testing an ARL3 variant in human retinal cells

  Human genetic study combined with laboratory stem-cell modeling.

  What was found:

  Phenotypes varied from rod-cone to cone-rod dystrophy, and the cells showed reduced delivery of important proteins into the cilium and outer segment.

  Why it matters:

  It was the first study of ARL3 dysfunction in human retinal cells, providing a model that could support future treatment research.

  Limitation: Cell models cannot fully reproduce the whole eye, and the number of families remains small.

• ARL3 as a cause of recessive cone-rod dystrophy

  Human observational study with functional validation.

  What was found:

  A homozygous ARL3 variant (R99I) segregated with disease, and lab work showed the affected amino acid is essential for ARL3 protein stability.

  Why it matters:

  It established ARL3 as a recessive cause of cone-rod dystrophy, broadening the range of disease linked to this gene.

  Limitation: Based on two related families; the specific variant may be rare in other populations.

• Confirming dominant ARL3 retinitis pigmentosa

  Human case study with structural analysis.

  What was found:

  The variant caused non-syndromic RP with early loss of central vision and appears to destabilize the protein's core structure; no other rare ARL3 variants were found in 431 other RP patients.

  Why it matters:

  It removed lingering doubt (a database "question mark") and confirmed ARL3 as a dominant RP gene.

  Limitation: Very few families with this exact variant have been described.

• Overview of ARL3 in retinal disease

  Review article.

  What was found:

  ARL3 regulates the enrichment of lipidated proteins essential for vision, and mutations cause both non-syndromic recessive and dominant retinal degeneration as well as syndromic Joubert syndrome with retinal dystrophy.

  Why it matters:

  It provides a clear picture of the range of ARL3-related disease and its underlying mechanism.

  Limitation: A review summarizes prior work rather than presenting new patient data.

Most ARL3-related disease in the reviewed reports affects only the eyes, but the gene is also linked to Joubert syndrome, a rarer condition that can involve the brain, kidneys, and other organs. If a syndromic form is suspected, families may benefit from coordinated monitoring beyond the eyes, which a clinician can help arrange. Recessive ARL3 disease can begin relatively early — one reported patient had noticeable vision problems in adolescence — so awareness of early symptoms in younger relatives may be helpful. Because both dominant and recessive inheritance occur, the implications for parents, siblings, and children differ, and a genetic counselor can explain what applies in your family.

• Does my ARL3 result appear to follow a dominant or recessive pattern, and what does that mean for my family?
• Which retinal diagnosis best fits my findings — retinitis pigmentosa, cone-rod dystrophy, or another form?
• Are there any signs of syndromic (non-eye) involvement that should be monitored given ARL3's link to Joubert syndrome?
• Given the reports of incomplete penetrance, how should unaffected relatives who carry the variant be counseled?
• What eye tests would best track how my condition changes over time?
• Are there registries or studies you would recommend I look into through the Clinical Trials Finder?

Confirming the specific ARL3 variant and its likely inheritance pattern with a genetic counselor can help clarify what the result may mean for you and your relatives. Because ARL3 disease can be dominant or recessive, it is worth discussing which pattern applies in your case, as this changes how relatives may be affected. To explore whether any current studies may be relevant, you can use RP Hope's Clinical Trials Finder, which lets you screen with ARL3 in mind rather than trying to judge eligibility on your own.